4D Molecular Therapeutics, Inc. (FDMT)Healthcare | Biotechnology | EmeryVille, United States | NasdaqGS
10.49 USD
+0.43
(4.274%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 10.57 +0.08 (0.763%) ⇧ (April 17, 2026, 7:19 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 1:37 p.m. EDT
FDMT is a high-risk, high-reward biotech stock with a volatile price history and negative earnings. The recent news includes positive earnings reports and management changes, but the stock has been trading within a narrow range. The forecasting model suggests a slight downward trend in the short term, and the options data indicates mixed sentiment. While the stock has a high market cap and some analyst recommendations, the fundamentals are weak, and the lack of dividends makes it unsuitable for income-focused investors. Short-term traders might consider the recent dips as potential buying opportunities, but long-term investors should be cautious due to the company's financial challenges and uncertain future. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.087772 |
| AutoETS | 0.088564 |
| AutoTheta | 0.090907 |
| AutoARIMA | 0.091307 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 55% |
| H-stat | 2.75 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.405 |
| Excess Kurtosis | -0.97 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.235 |
| Revenue per Share | 1.471 |
| Market Cap | 535,530,112 |
| Forward P/E | -2.72 |
| Beta | 2.93 |
| Profit Margins | -164.43% |
| Website | https://www.4dmoleculartherapeutics.com |
As of April 11, 2026, 1:37 p.m. EDT: Options activity shows mixed signals. For the near-term expirations (April 17 and May 15), there's a concentration of open interest and volume around the $10 strike, suggesting some speculative activity. However, the IV is relatively low, indicating limited volatility expectations. For further out expirations (July 17 and October 16), there's a focus on lower strikes with higher open interest, suggesting potential bearish sentiment. The ATM strikes are often seen as anchors, but the overall positioning doesn't indicate a clear directional bias. The presence of both calls and puts with significant open interest implies uncertainty and possible range-bound trading.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.2662337 |
| Address1 | 5,858 Horton Street |
| Address2 | Suite 455 |
| All Time High | 55.11 |
| All Time Low | 2.235 |
| Ask | 10.53 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 726,760 |
| Average Daily Volume3 Month | 765,596 |
| Average Volume | 765,596 |
| Average Volume10Days | 726,760 |
| Beta | 2.933 |
| Bid | 10.47 |
| Bid Size | 3 |
| Board Risk | 6 |
| Book Value | 8.778 |
| City | EmeryVille |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 10.49 |
| Current Ratio | 9.393 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 10.74 |
| Day Low | 10.21 |
| Debt To Equity | 4.235 |
| Display Name | 4D Molecular Therapeutics |
| Earnings Timestamp | 1,773,864,000 |
| Earnings Timestamp End | 1,778,184,000 |
| Earnings Timestamp Start | 1,778,184,000 |
| Ebitda | -151,652,992 |
| Ebitda Margins | -1.7797799 |
| Enterprise To Ebitda | -1.017 |
| Enterprise To Revenue | 1.811 |
| Enterprise Value | 154,288,096 |
| Eps Current Year | -3.8256 |
| Eps Forward | -3.855 |
| Eps Trailing Twelve Months | -2.52 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 9.2626 |
| Fifty Day Average Change | 1.2273998 |
| Fifty Day Average Change Percent | 0.13251138 |
| Fifty Two Week Change Percent | 226.62337 |
| Fifty Two Week High | 12.34 |
| Fifty Two Week High Change | -1.8500004 |
| Fifty Two Week High Change Percent | -0.14991899 |
| Fifty Two Week Low | 2.96 |
| Fifty Two Week Low Change | 7.5299997 |
| Fifty Two Week Low Change Percent | 2.5439188 |
| Fifty Two Week Range | 2.96 - 12.34 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,607,697,000,000 |
| Float Shares | 35,260,752 |
| Forward Eps | -3.855 |
| Forward P E | -2.7211413 |
| Free Cashflow | -54,154,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 196 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | -1.2591001 |
| Gross Profits | -107,287,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03612 |
| Held Percent Institutions | 1.06888 |
| Implied Shares Outstanding | 51,051,487 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-12-11 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | 4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California. |
| Long Name | 4D Molecular Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 535,530,112 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_272879653 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -140,108,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 514,088,474 |
| Number Of Analyst Opinions | 9 |
| Open | 10.4806 |
| Operating Cashflow | -109,082,000 |
| Operating Margins | 0.17411 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 510 505 2680 |
| Post Market Change | 0.07999992 |
| Post Market Change Percent | 0.76263034 |
| Post Market Price | 10.57 |
| Post Market Time | 1,776,467,940 |
| Previous Close | 10.06 |
| Price Eps Current Year | -2.7420535 |
| Price Hint | 2 |
| Price To Book | 1.1950331 |
| Price To Sales Trailing12 Months | 6.2849007 |
| Profit Margins | -1.6443 |
| Quick Ratio | 9.154 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | 0.429999 |
| Regular Market Change Percent | 4.27435 |
| Regular Market Day High | 10.74 |
| Regular Market Day Low | 10.21 |
| Regular Market Day Range | 10.21 - 10.74 |
| Regular Market Open | 10.4806 |
| Regular Market Previous Close | 10.06 |
| Regular Market Price | 10.49 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 894,935 |
| Return On Assets | -0.1734 |
| Return On Equity | -0.27573 |
| Revenue Growth | 85,089.0 |
| Revenue Per Share | 1.471 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 51,051,487 |
| Shares Percent Shares Out | 0.21280001 |
| Shares Short | 10,862,832 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 10,132,423 |
| Short Name | 4D Molecular Therapeutics, Inc. |
| Short Percent Of Float | 0.2207 |
| Short Ratio | 13.06 |
| Source Interval | 15 |
| State | CA |
| Symbol | FDMT |
| Target High Price | 38.0 |
| Target Low Price | 17.0 |
| Target Mean Price | 28.77778 |
| Target Median Price | 29.0 |
| Total Cash | 402,655,008 |
| Total Cash Per Share | 7.887 |
| Total Debt | 21,413,000 |
| Total Revenue | 85,209,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.52 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.35695 |
| Two Hundred Day Average Change | 2.13305 |
| Two Hundred Day Average Change Percent | 0.25524265 |
| Type Disp | Equity |
| Volume | 894,935 |
| Website | https://www.4dmoleculartherapeutics.com |
| Zip | 94,608 |